Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pearl Lee

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Genes & Development|August 16, 2012
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayCatherine Andreadi, Lai-Kay Cheung, Susan Giblett, et al.
Pain Management|April 23, 2026
Patient perspectives on non‑traumatic painful upper‑extremity conditions, co-occurring risky substance use, and an integrated web-based mind-body intervention addressing both conditionsJulie R Brewer, Pearl Lee, Nadine Levey, et al.
Mededpublish (2016)|September 22, 2023
Framework for virtual education of COVID-19 vaccines for Mandarin-speaking learners: an educational intervention moduleJiCi Wang, Benjamin M Moy, Ross T Kaufhold, et al.
Diabetes Care|July 26, 2022
Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications StudyCatherine L Martin, Victoria R Trapani, Jye-Yu C Backlund, et al.
Nature Cell Biology|May 6, 2020
FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretomeFuming Li, Peiwei Huangyang, Michelle Burrows, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Scientific Reports|May 14, 2017
Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivoAndreas K Hock, Eric C Cheung, Timothy J Humpton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsWarren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Diabetes Care|August 14, 2020
An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC StudyIonut Bebu, Barbara H Braffett, David Schade, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Genes & Development|August 16, 2012
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathwayCatherine Andreadi, Lai-Kay Cheung, Susan Giblett, et al.
Pain Management|April 23, 2026
Patient perspectives on non‑traumatic painful upper‑extremity conditions, co-occurring risky substance use, and an integrated web-based mind-body intervention addressing both conditionsJulie R Brewer, Pearl Lee, Nadine Levey, et al.
Mededpublish (2016)|September 22, 2023
Framework for virtual education of COVID-19 vaccines for Mandarin-speaking learners: an educational intervention moduleJiCi Wang, Benjamin M Moy, Ross T Kaufhold, et al.
Diabetes Care|July 26, 2022
Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications StudyCatherine L Martin, Victoria R Trapani, Jye-Yu C Backlund, et al.
Nature Cell Biology|May 6, 2020
FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretomeFuming Li, Peiwei Huangyang, Michelle Burrows, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Scientific Reports|May 14, 2017
Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivoAndreas K Hock, Eric C Cheung, Timothy J Humpton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsWarren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Diabetes Care|August 14, 2020
An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC StudyIonut Bebu, Barbara H Braffett, David Schade, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Pageof 5